BMY

Bristol-Myers Squibb
D

BMY

Arincen68/100B

Bristol-Myers Squibb executives and insider trading

Christopher S. Boerner reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Bristol-Myers Squibb's insiders sold 40,549 shares for 2.53M USD in 5 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
5
Shares sold
40,549
Value sold
2.53M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
240.58K USD
0
3 months
677.83K USD
0
6 months
677.83K USD
0
1 year
2.53M USD
412.31K USD
2 years
5.20M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
David V. Elkins Executive Vice President & Chief Financial Officer5830,0001.85M USD—1 Apr 2026—
Cristian Massacesi Executive Vice President, Chief Medical Officer & Head of Development576,249403.50K USD—9 Sept 2026—
Julia A Haller Director—3,800240.58K USD—5 Nov 2026—
Phil M Holzer SVP and Controller—50033.75K USD—25 Aug 2026—

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
5 Nov 2026Julia A HallerSale3,80063.31240.58K USD30,279Form 4
9 Sept 2026Cristian MassacesiSale6,24964.57403.50K USD18,748Form 4
25 Aug 2026Phil M HolzerSale50067.5033.75K USD16,862Form 4
1 Apr 2026David V. ElkinsSale25,51961.601.57M USD163,729Form 4
1 Apr 2026David V. ElkinsSale4,48162.05278.05K USD159,248Form 4
2 Sept 2025David V. ElkinsSale56,00047.332.65M USD167,379Form 4
2 Aug 2025Bartie Wendy ShortSale37844.2316.72K USD5,066Form 4
9 May 2025Benjamin HickeySale9738.013.70K USD—Form 4
25 Apr 2025Samit HirawatPurchase4,25047.58202.22K USD83,513Form 4
20 Feb 2025Christopher S. BoernerPurchase2,00055.05110.10K USD104,626Form 4
14 Feb 2025Samit HirawatPurchase1,82354.84100.00K USD63,932Form 4

Common questions about Bristol-Myers Squibb's executives and insiders

Source: Financial Modeling PrepVerified against SEC filings